Discovery of new epigenomics-based biomarkers and the early diagnosis of neurodegenerative diseases.

Autor: Lee D; Department of Brain & Cognitive Sciences, DGIST, Daegu, Republic of Korea. Electronic address: cloudavin@gmail.com., Choi YH; Department of New Biology, DGIST, Daegu, Republic of Korea. Electronic address: ychoi@dgist.ac.kr., Seo J; Department of Brain & Cognitive Sciences, DGIST, Daegu, Republic of Korea. Electronic address: jsseo@dgist.ac.kr., Kim JK; Department of New Biology, DGIST, Daegu, Republic of Korea. Electronic address: jkkim@dgist.ac.kr., Lee SB; Department of Brain & Cognitive Sciences, DGIST, Daegu, Republic of Korea. Electronic address: sblee@dgist.ac.kr.
Jazyk: angličtina
Zdroj: Ageing research reviews [Ageing Res Rev] 2020 Aug; Vol. 61, pp. 101069. Date of Electronic Publication: 2020 May 19.
DOI: 10.1016/j.arr.2020.101069
Abstrakt: Treatment options for many neurodegenerative diseases are limited due to the lack of early diagnostic procedures that allow timely delivery of therapeutic agents to affected neurons prior to cell death. While notable advances have been made in neurodegenerative disease biomarkers, whether or not the biomarkers discovered to date are useful for early diagnosis remains an open question. Additionally, the reliability of these biomarkers has been disappointing, due in part to the large dissimilarities between the tissues traditionally used to source biomarkers and primarily diseased neurons. In this article, we review the potential viability of atypical epigenetic and/or consequent transcriptional alterations (ETAs) as biomarkers of early-stage neurodegenerative disease, and present our perspectives on the discovery and practical use of such biomarkers in patient-derived neural samples using single-cell level analyses, thereby greatly enhancing the reliability of biomarker application.
(Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: